Royalty Pharma plc (RPRX) insider trading.
In Q3 2026, insiders at Royalty Pharma plc reported 17 non-derivative transactions on 11 Forms 3, 4 and 5: 0 open-market purchases and 11 sales worth $20.6M.
- Transactions
- 17
- Purchases (P)
- 0
- Sales (S)
- 11
- Net shares, P minus S
- -354,227
- Insiders
- 5
- Last filed
- 2026-09-30
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Hite Christopher | Officer · EVP & Chairman, Partnering | 9 | 0 | 7 |
| Urist Marshall | Officer · EVP, Research & Investments | 3 | 0 | 2 |
| Coyne Terrance P. | Officer · EVP & CFO | 3 | 0 | 2 |
| Bassler Bonnie L | Director | 1 | 0 | 0 |
| Legorreta Pablo G. | Director, Officer · CEO, Chairman of the Board | 1 | 0 | 0 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-30 | Bassler Bonnie L | A (A) | 642 | $58.41 | 79,823 | Form 4 |
| 2026-09-28 | Urist Marshall | S (D) | 4,126 | $57.88 | 4,126 | Form 4 |
| 2026-09-22 | Hite Christopher | S (D) | 96,073 | $58.51 | 274,328 | Form 4 |
| 2026-09-22 | Hite Christopher | S (D) | 3,927 | $58.93 | 270,401 | Form 4 |
| 2026-08-19 | Hite Christopher | G (D) | 16,800 | $0 | 23,200 | Form 4 |
| 2026-08-18 | Hite Christopher | S (D) | 100,000 | $59.97 | 370,401 | Form 4 |
| 2026-08-13 | Coyne Terrance P. | S (D) | 9,230 | $58.59 | 1,772 | Form 4 |
| 2026-08-13 | Coyne Terrance P. | S (D) | 1,772 | $59.14 | 0 | Form 4 |
| 2026-08-05 | Legorreta Pablo G. | A (A) | 65,216 | $0 | 1,307,820 | Form 4 |
| 2026-08-05 | Hite Christopher | A (A) | 11,002 | $0 | 470,401 | Form 4 |
| 2026-08-05 | Coyne Terrance P. | A (A) | 11,002 | $0 | 11,002 | Form 4 |
| 2026-08-05 | Urist Marshall | A (A) | 8,252 | $0 | 8,252 | Form 4 |
| 2026-07-01 | Urist Marshall | S (D) | 9,099 | $55.88 | 0 | Form 4 |
| 2026-06-30 | Hite Christopher | S (D) | 2,554 | $57.1 | 459,399 | Form 4 |
| 2026-06-30 | Hite Christopher | S (D) | 97,446 | $56.5 | 461,953 | Form 4 |
| 2026-06-30 | Hite Christopher | S (D) | 600 | $57.09 | 40,000 | Form 4 |
| 2026-06-30 | Hite Christopher | S (D) | 29,400 | $56.44 | 40,600 | Form 4 |
Transaction codes in this quarter
Get RPRX insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1802768&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · RPRX company page · Royalty Pharma plc on SEC.gov
Questions
Are insiders buying or selling Royalty Pharma plc (RPRX)?
In Q3 2026, insiders at Royalty Pharma plc reported 17 non-derivative transactions on 11 Forms 3, 4 and 5: 0 open-market purchases and 11 sales worth $20.6M. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Royalty Pharma plc insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/rprx.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.